Two leases on LIF

How Northern targets both tumor immunosuppression and self-renewal

While most immuno-oncology products in the clinic target the immunosuppressive factors that help tumors evade an attack, Northern Biologics Inc.'s anti-LIF antibody takes a step further. By simultaneously blocking both immunosuppression and self-renewal of cancer stem cells the newco expects the antibody to be effective against a wider range of cancers than other immuno-oncology programs.

Northern was launched in 2014 by Versant Ventures to develop cancer and fibrosis

Read the full 678 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE